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a b s t r a c t 
The peptide hormone apelin is translated as a 77-residue preproprotein, truncated to the 55-residue 
proapelin and, subsequently, to 13–36-residue bioactive isoforms named apelin-13 to -36. Proapelin 
is hypothesized to be cleaved to apelin-36 and then to the shorter isoforms. However, neither the 
mechanism of proapelin processing nor the endoproteases involved have been determined. We show 
direct cleavage of proapelin to apelin-13 by proprotein convertase subtilisin / kexin 3 (PCSK3, or furin) 
in vitro , with no production of longer isoforms. Conversely, neither PCSK1 nor PCSK7 has appreciable 
proapelin cleavage activity. Furthermore, we show that both proapelin and PCSK3 transcript expression 
levels are increased in adipose tissue with obesity and during adipogenesis, suggesting that PCSK3 is 
responsible for proapelin processing in adipose tissue. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. Open access under CC BY-NC-SA license. . Introduction 
Apelin is a peptide hormone present in many tissues and body 
uids [ 1 ]. It is known to be a potent cardiac inotrope [ 2 ] and to modu-
ate blood pressure [ 3 ]. Furthermore, apelin and its cognate G-protein 
oupled receptor (the apelin receptor) [ 4 ] are expressed in adipose 
issue with signiﬁcantly increased expression correlated to obesity 
 5 ]. Apelin was recently shown to inhibit adipocyte differentiation 
nd breakdown of fat [ 6 ] and improve insulin sensitivity [ 7 ]. Thus, 
he apelin signalling system has been touted as having great thera- 
eutic potential in treatment of obesity and cardiovascular diseases 
 3 , 7 , 8 ]. 
Apelin is expressed as a 77 residue pre-proprotein, which is Abbreviations: MALDI-MS, matrix assisted laser desorption ionization mass spec- 
rometry; PCSK, proprotein convertase subtilisin / kexin; RP-HPLC, reverse phase high 
erformance liquid chromatography; (q)PCR, (quantitative) polymerase chain reaction; 
T-PCR, reverse transcription-PCR; TEV, tobacco etch virus. 
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ttp://dx.doi.org/10.1016/j.fob.2013.08.001 cleaved to a 55 residue proprotein (proapelin) following removal 
of an N-terminal signal peptide [ 8 ]. In all bioactive forms of apelin, 
at least 12 residues at the C-terminus of proapelin are retained [ 9 ]. 
The current proposed mechanism for apelin processing suggests that 
proapelin is ﬁrst cleaved to form apelin-36 ( i.e. , the 36 C-terminal 
residues of proapelin) in the cell and then further processed into 
shorter apelin isoforms retaining the C-terminus, most prevalently 
13 and 17 amino acids long [ 3 ]. Spontaneous cyclization of the N- 
terminal Gln of apelin-13 produces the pyroglutamate-modiﬁed form 
(Pyr-apelin-13) [ 10 ]. All apelin isoforms bind to the apelin receptor 
to cause similar cellular effects; however, isoform potencies, efﬁca- 
cies, and receptor recycling kinetics differ [ 1 , 11 ]. Furthermore, studies 
have shown that there is tissue speciﬁcity in apelin isoforms pro- 
duction. For example, Pyr-apelin-13 is the dominant isoform present 
throughout the brain, hypothalamus, and heart, but the predominant 
isoform in the lungs, testis, and uterus is apelin-36 [ 12 –14 ]. Despite 
this variability in isoform activity and localization, no studies have 
directly investigated proapelin processing or the endoproteases in- 
volved [ 1 , 3 ]. 
One of the endoprotease families known to activate prohormones 
is the proprotein convertase subtilisin / kexin (PCSK) family, compris- 
ing nine known subtypes of Ca 2 + dependent endoproteases, known 
as PCSK1 through PCSK9 [ 15 ]. Substrates of many PCSKs contain diba- 
sic residues immediately N-terminal to the cleavage site and usually 
have a β-turn at or near the cleavage site [ 16 ]. Since, proapelin has 
multiple dibasic motifs ( Fig. 1 A) and a β-turn at the cleavage site of 
apelin-13 [ 17 ], we hypothesized that PCSK enzymes are responsible ean Biochemical Societies. Open access under CC BY-NC-SA license.
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 for proapelin cleavage. 
In this report, we demonstrate for the ﬁrst time proapelin cleav-
age into a bioactive isoform. Strikingly, PCSK3 directly and prefer-
entially cleaves proapelin into apelin-13 in vitro with no evidence of
longer isoforms. In contrast, neither PCSK1 nor PCSK7 shows appre-
ciable proapelin cleavage activity. Furthermore, we show that both
proapelin and PCSK3 transcript expression levels are increased in
adipose tissue with obesity and during adipogenesis suggesting that
PCSK3 is responsible for proapelin processing in adipose tissues. 
2. Materials and methods 
2.1. Proapelin expression and puriﬁcation 
To produce proapelin, proapelin (synthetic gene with Escherichia
coli codon bias, BioBasic) with 6xHis tag and TEV protease cleavage
site was cloned into the pEXP5-NT vector (Invitrogen) and expressed
in E. coli C41(DE3) (Lucigen). The protein was puriﬁed by Ni-NTA
agarose column (Qiagen). The 6xHis tag was cleaved by TEV protease
(Addgene). Proapelin was puriﬁed by S Ceramic HyperD F cation ex-
change column (PALL Life Science). 
2.2. In vitro enzymatic digestions 
Active recombinant PCSKs (2 μg; RnD Systems) were mixed with
proapelin (75 nmol) in appropriate buffer (PCSK1: 25 mM acetate or
2-( N -morpholino) ethanesulfonic acid, 5 mM CaCl 2 , 1% Brij-35, pH 6;
PCSK3: 25 mM Tris or acetate, 1 mM CaCl 2 , 1% Brij-35, pH 5–7; PCSK7:
25 mM Tris, 0.4–1.5 mM CaCl 2 , 0.5% Brij-35, pH 7). In each case, the
reaction was monitored at various time points by reverse phase high
performance liquid chromatography (RP-HPLC) separation (Varian
ProStar HPLC) using an analytical column C18-AR-II (4.6 × 250 mm,
Cosmosil). The mobile phase components were Type II water (A) and
acetonitrile (B), both containing 0.1% triﬂuoroacetic acid (v / v). Elution
was carried out at a ﬂow rate of 1 ml / min using a linear gradient from
2–100% B in A (2–20% in 5 min, 20–40% in 20 min, 40–100% in 15 min,
and 100–2% in 2 min) or 2–40% (2–20% in 3 min, 20–40% in 20 min,
and 40–2% in 2 min). UV chromatograms were recorded at 210 and
280 nm simultaneously and eluent masses determined by matrix-
assisted laser desorption / ionization mass spectrometry (MALDI-MS,
C-CART Facility at Memorial University, St. John ’ s, Newfoundland). 
2.3. 3T3-L1 preadipocyte differentiation 
3T3-L1 preadipocytes were obtained from ATCC (Manassas, Vir-
ginia) then subjected to differentiation [ 18 ]. Passages 4–10 were used
for experiments, and tested negative for mycoplasma. Preadipocytes
were seeded in 6-well plates and grown to conﬂuence. At 2 days
post-conﬂuence (day 0), differentiation was initiated by changing
the medium to induction media (DMEM containing 10% FBS, 1 μM
dexamethasone (DEXA, D2915, Sigma Aldrich), 0.5 mM 3-isobutyl-
1-methylxanthine (IBMX, I7018, Sigma Aldrich), and 1 μg / ml human
insulin (HI-210, Eli Lilly) [ 18 ]. On day 2, the medium was replaced with
insulin-containing medium (DMEM supplemented with 10% FBS, 1%
P / S, and 10 μg / ml human insulin). Thereafter, the medium was re-
placed at 2-day intervals with FBS media (DMEM supplemented with
10% FBS). Differentiated cells were observed starting at day 4 and
more than 90% of the cells were fully differentiated by day 8. During
the differentiation protocol, mRNA was extracted from adipocytes
and analyzed for proapelin and PCSKs expressions by RT-PCR. mRNA
was extracted using Aurum Total RNA Fatty and Fibrous Tissue Kit
(BioRad) following the manufacturer’s guidelines. 2.4. Animals and tissue preparation 
All animal studies were approved by the Dalhousie University An-
imal Care Committee and were performed in strict adherence to the
policies of the Canadian Council for Animal Care. 6 week old male
B6.V-Lep (ob) / j ob / ob mice and 12 week old male C57BL / 6J mice that
were fed a high fat diet (60% fat, 20% carbohydrate, 20% protein) from
weeks 6 to 12, and their age matched controls who were fed a lower
fat diet (10% fat, 70% carbohydrate, 20% protein) were purchased from
Jackson Laboratory. Peri-gonadal white adipose tissues were removed
and immediately snap frozen in liquid nitrogen, then stored at −80 ◦C
until use. RNA extraction, cDNA synthesis and reverse transcription
from tissues and cells were conducted as described previously [ 19 ].
Tissues extracted from control, DIO, and ob / ob mice were analyzed
for the proapelin and PCSK3 mRNA by RT-PCR. The values are repre-
sented as mean ± standard deviation. 
2.5. Real time PCR 
All qPCR reactions were performed using 2 A˚ ∼Brilliant SYBR green
master mix (Roche) with initial denaturation at 95 ◦C for 10 min
followed by 40 cycles at 95 ◦C for 30 s, 60 ◦C for 1 min and 72 ◦C
for 30 s. A list of all primers used is provided in the Supplementary
Information ( Table S1 ). mRNA concentrations were determined from
a standard curve of known concentration amplicons. The amounts
of mRNA were extrapolated from standard curves, and all data are
expressed relative to 18S RNA (% 18S). 
2.6. Statistical analysis 
Data analysis was performed using Prism (v5.0, Graphpad). Data
are reported as mean ± SEM. One way ANOVA was used for multiple
comparisons between mouse strains, followed by Tukey’s post hoc
test. p < 0.05 was considered signiﬁcant. 
3. Results and discussion 
3.1. PCSK3 preferentially activates proapelin into apelin-13 
We initially studied the PCSK-mediated apelin processing with
PCSK3 (also known as furin) because it is the most well studied PCSK
subtype that cleaves C-terminally to dibasic sites. In addition, expres-
sion of PCSK3 is detected in tissues secreting apelin, such as the heart
[ 20 ] and adipose tissue [ 21 ], suggesting the possibility for apelin pro-
cessing by PCSK3. 
Recombinant proapelin was produced in E. coli with an N-terminal
His-tag, puriﬁed following proteolysis to remove the His-tag, and in-
cubated with PCSK3 in vitro to test its suitability for cleavage by PSCK3.
It should be noted that our recombinant proapelin retains an addi-
tional N-terminal Ser as a result of TEV protease cleavage. Proapelin
assays were conducted at 37 ◦C and at pH 5, 6, and 7 to investigate
the process across the pH gradient found along the secretory path-
way [ 22 ]. Crude reaction mixture samples at given time points were
subjected to RP-HPLC using a mobile phase gradient optimized for
separation of apelin isoforms (details in the Supplementary Infor-
mation ). The constituents of all resulting peptide / protein containing
fractions were identiﬁed by mass spectrometry. 
Incubation of the 56 residue proapelin (6259 m / z ) with PCSK3 re-
sulted in production of two polypeptide species with distinct RP-HPLC
elution properties at all tested pH conditions. These species were un-
ambiguously identiﬁable as apelin-13 (1550.5 m / z , aa 44–56) and the
N-terminal of proapelin (the “pro-domain”, 4709 m / z , aa 1–43) ( Fig.
1 B–D). Notably, these eluents were not observed when proapelin was
incubated in the absence of PCSK3 ( Fig. S1 ). Under all reaction con-
ditions, both the pro-domain and uncleaved proapelin had a mass
16 m / z greater than expected, suggesting that oxidization had taken
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Fig. 1. PCSK3 preferentially cleaves proapelin into apelin-13. Proapelin produced and puriﬁed from E. coli was incubated with recombinant PCSK3. (A) Proapelin and its fragments 
alongside predicted molecular weights and numbered 1–3 according to elution time. The gray Ser at the N-terminus is retained residue following TEV protease cleavage; the 
green residues represent the endogenous 42 amino acid N-terminal pro-domain; blue represents the 13 residue apelin-13, with 1* being Pyr-apelin-13. Proapelin incubation with 
PCSK3 resulted in production of 3 new products corresponding to apelin-13, Pyr-apelin-13, and the 43 amino acid N-terminal pro domain at (B) pH 7 (C) pH 6 and (D) pH 5. (For 
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.) 
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ilace. Following a 5-h incubation, the concentrations of apelin-13 
nd the pro-domain consistently exceeded that of proapelin at both 
H 6 and 7. At the 5-h time point, another product became visible 
ith a mass consistent with Pyr-apelin-13 (1533.8 m / z ), presumably 
rising from spontaneous cyclization of the apelin-13 N-terminal Gln 
 10 ]. At pH 5, PCSK3 showed decreased enzymatic activity similar to 
revious studies [ 23 ] but the same preferential cleavage to apelin-13 
nd the pro-domain ( Fig. 1 D). In no instance were cleavage products 
bserved corresponding to production of any of the longer or shorter 
pelin isoforms. 
Many PCSK3 substrates have a β-turn at their cleavage site and 
 consensus amino acid sequence N-terminal to the cleavage site of 
-(X)-K / R-R, with X representing any amino acid other than Cys [ 15 ]. 
xceptions to the consensus sequence are also observed, and it is 
he last two basic amino acids that are believed to be most critical 
or cleavage [ 24 ]. Strikingly, our previous structural investigations of 
pelin-17 demonstrated a β-turn over the residues R ↓ Q-R-P (with 
he apelin-13 cleavage site indicated by ↓ ) [ 17 ]. Furthermore, the se- 
uence immediately N-terminal to the cleavage site is K-F-R-R, sim- 
lar to the consensus sequence required by PCSK3 in terms of basic residues ( Fig. 1 A). Interestingly, apelin-17, which also has two Arg 
residues immediately N-terminal to its cleavage site, was not pro- 
duced by PCSK3. This may simply be due to much lower afﬁnity of 
PCSK3 to cleave following the G-G-R-R sequence N-terminal to apelin- 
17 vs. the K-F-R-R N-terminal to apelin-13. Alternatively, the absence 
of apelin-17 production may be due to the presence of ordered struc- 
tures such as α-helices or β-strands upstream of apelin-17 cleavage 
site since structuring is associated with non-cleaved sites [ 24 ]. To 
date, no structural data is available for any apelin isoform longer 
than apelin-17 but circular dichroism studies of apelin-36 are cer- 
tainly not indicative of extensive stable secondary structure [ 17 , 25 ]. 
In general, not all putative cleavage sites are processed by PCSKs, and 
the recognition of endoproteases is not correlated with the existence 
of a single consensus primary sequence around cleaved sites. Corre- 
spondingly, many factors involved in PCSK-mediated processing are 
still unknown. Therefore, it is difﬁcult to attribute any single factor to 
the absence of apelin-17 production. 
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Fig. 2. Proapelin, PCSK3 and PCSK7 mRNA expression are increased with adipocyte differentiation and obesity in mice. (A, B) During the differentiation protocol, mRNA was 
extracted from adipocytes and analyzed for proapelin and PCSKs expressions by RT-PCR. (C, D) Tissues were extracted from 12-week old control, DIO, and ob / ob mice and the 
proapelin and PCSK3 mRNA expressions were analyzed by RT-PCR. The values are represented as mean ± standard deviation. 
Fig. 3. Overview of proposed apelin processing pathways. (A) The previously proposed mechanism for apelin processing [ 3 ] suggested that proapelin is cleaved to the longest 
isoform, apelin-36, and then further processed to shorter isoforms with increased efﬁcacy. (B) Our new model of apelin processing suggests that PCSK3 directly produces apelin-13 
from proapelin. The longer apelin-36 and -17 isoforms are putatively produced by other, as yet unidentiﬁed endoproteases. 
 
 
 
 
 
 
 
 
 3.2. PCSK1 and PCSK7 do not cleave proapelin in vitro 
We also investigated the capability of the neuroendocrine
system-speciﬁc PCSK1 and ubiquitously expressed PCSK7 to process
proapelin. During screening for cleavage by PCSK1 and 7, various Ca 2 + 
concentrations and buffer compositions were employed, following
previously reported optimized reaction conditions [ 23 , 26 , 27 ]. In thecase of PCSK1, lower speciﬁc activity than PCSK3 was expected [ 28 ].
However, even after 3 days of incubation of proapelin with PCSK1, no
processing to bioactive apelin isoforms was evident ( Fig. S2 ). PCSK7,
alternatively, has similar speciﬁc activity to PCSK3, and is known to
process some of the same substrates [ 29 ]. Despite this, no evidence
of proapelin cleavage by PCSK7 was observed ( Fig. S2 ). 
332 Kyungsoo Shin et al. / FEBS Open Bio 3 (2013) 328–333 
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v.3. Proapelin and PCSK subtype expression levels correlate with 
dipocyte differentiation and obesity 
Apelin is expressed in adipose tissue and its expression increases 
ith obesity [ 30 , 31 ]. To determine if proapelin and PCSK3 expression 
evels change during preadipocyte differentiation, mRNA levels were 
onitored over the course of the differentiation process of 3T3-L1 
readipocytes. Proapelin expression showed a sigmoidal increase in 
xpression during early differentiation and peaked near day 5 ( Fig. 
 A). Notably, both PCSK3 and PCSK7 mRNA levels increased dur- 
ng differentiation, but differed in their expression proﬁles ( Fig. 2 B). 
CSK1 mRNA, conversely, remains at its basal level throughout the 
rocess. PCSK3 expression levels exhibited bimodal behaviour, with 
eak expression at day 2 and 7, but remained relatively high after day 
 compared to other PCSK subtypes. PCSK7 expression remained low 
elative to PCSK3 until day 6 of differentiation, at which it started to 
ncrease. Therefore, high PCSK3 levels correlate strongly to increasing 
roapelin expression during adipocyte differentiation. 
To test this correlation in vivo , we investigated the expression of 
roapelin and PCSK3 expression in white adipose tissue from lep- 
in deﬁcient ob / ob mice and diet-induced obese mice. mRNA was 
xtracted from peri-gonadal white adipose tissue from 12-week-old 
ice and analyzed expression using quantitative PCR. Proapelin and 
CSK3 expression levels were signiﬁcantly increased in mouse mod- 
ls of obesity compared to the lean controls ( Fig. 2 C and D). Given 
he high co-expression of PCSK3 and proapelin, apelin-13 may be the 
referred isoform in adipose tissue. PCSK3 has also been shown to be 
ighly expressed in the heart [ 20 ], suggesting that the prevalence of 
pelin-13 in this tissue may also be due to PCSK3. 
.4. A new proposed mechanism for apelin isoform production 
Apelin is present in the body as many bioactive isoforms with 
otential tissue speciﬁc processing. We show for the ﬁrst time that 
 speciﬁc endoprotease, PCSK3, is capable of producing apelin-13. 
he current proposed mechanism of apelin processing suggests that 
roapelin is initially cleaved to apelin-36 then further cleaved into 
horter isoforms of increasing efﬁcacies ( Fig. 3 A) [ 3 ]. However, we 
how that PCSK3 speciﬁcally and preferentially produces apelin-13 
irectly from proapelin without evidence of any apelin-36 or apelin- 
7 production. Furthermore, we showed that PCSK1 and 7 could not 
leave proapelin, suggesting a speciﬁcity of PCSK3 for proapelin pro- 
essing. We therefore propose a new mechanism of apelin processing 
n which proapelin is cleaved to various bioactive isoforms directly 
rom its proprotein stage by various endoproteases, including PCSK3 
 Fig. 3 B). Although many regulators and other enzymes involved in 
roapelin processing still remain unknown, identifying PCSK3 as one 
f the proteases involved in processing is a key ﬁrst step towards un- 
aveling of apelin isoform level and activity differences as a function 
f both tissue type and of healthy or pathological conditions. 
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